0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï »ýÁ¸ÀÚ¿Í Á߳⿩¼ºÀÇ °»³â±â Áõ»ó ¹× ÀÎÁö±â´É ºñ±³

Comparison of Climacteric Symptoms and Cognitive Impairment in Breast Cancer Survivors and Healthy Women

Á¾¾ç°£È£¿¬±¸ 2013³â 13±Ç 1È£ p.11 ~ 17
KMID : 1035120130130010011
±è°æ´ö ( Kim Gyung-Duck ) - µ¿¾ç´ëÇб³ °£È£Çаú

Á¤º¹·Ê ( Chung Bok-Yae ) - °æºÏ´ëÇб³ °£È£´ëÇÐ
±è°æÇý ( Kim Kyug-Hae ) - ±èõ´ëÇб³ °£È£Çаú
º¯Çý¼± ( Byun Hye-Sun ) - ¼ö¼º´ëÇб³ °£È£Çаú
ÃÖÀºÈñ ( Choi Eun-Hee ) - ¿µ³²ÀÌ°ø´ëÇб³ °£È£Çаú

Abstract

Purpose: This study was to compare climacteric symptoms and cognitive impairment in breast cancer survivors (n=51) and healthy women (n=51).

Methods: This study was conducted from January 4th, 2012 to February 16th, 2012. We individually matched healthy women to breast cancer survivors based on age and education, and assessed a questionnaire regarding climacteric symptoms and cognitive impairment. Data were analyzed by using ¥ö©÷, t-test, and Pearson correlation with the SPSS/Win 12.0 program.

Results: The average score for the climacteric symptoms (19.71) was significantly different (t=-2.78, p=.006) to the average for the breast cancer survivors (15.53). The average cognitive impairment score for the breast cancer survivors (86.37) was significantly different (t=-2.45, p=.016) to the average score for the healthy women (67.92). The climacteric symptoms score showed a significant relationship with cognitive impairment.

Conclusion: These results support that adjuvant chemotherapy and anti-hormone therapy are associated with climacteric symptoms and adverse cognitive effects in breast cancer survivors.
KeyWords
À¯¹æ¾Ï »ýÁ¸ÀÚ, °»³â±â Áõ»ó, Àαâ±â´É
Breast Neoplasms, Survivors, Climacteric, Symptoms, Cognitive Disorder
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed